Protection assessments indicated that gastrointestinal adverse activities, generally nausea and diarrhea, have been dose-dependent but commonly delicate and transient. These results set up the therapeutic window and knowledgeable dose choice for subsequent Stage three trials.Continued refinement of formulation and dosing strategies could ad… Read More